Figure 4.
NPY1R receptor antagonist (BIBP-3222) significantly reduced serum IL-6 and histological damage in T-cell transfer colitis model. A, RAG1 knockout mice were injected with 0.5 × 106 CD45RB+ high T cells intraperitoneally (day 1). On day 2, the mice received the first dose of NPY Y1 (BIBP-3222) or NPY2R (BIIE-0246) antagonists via intracolonic injections, after which the mice received NPY antagonists once a week up to week 8. Body weights were taken every week initially up to 3 weeks; and starting week 4, mice were monitored twice daily for body weight. At the end of 8 weeks, mice were killed humanely, and tissues were collected. B, Body weight loss at the end of 8 weeks. C, Colon morphology. D, H&E staining showing histological damage and (E) histological score. Real time PCR showing (F) colonic NPY mRNA and (G) colonic TNF mRNA. Values are mean ± SEM, n = 5-6. Magnification 20x, scale bar 50 µm. One-way ANOVA followed by Dunnett multiple comparison test, significant differences compared with the colitic group expressed as *P < .05.